SciELO - Scientific Electronic Library Online

vol.32 issue1Incidental maternal death due to lightning injury: a case report author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Medicas UIS

Print version ISSN 0121-0319


DIAZTAGLE, Juan José; CASTRO, Carlos Alberto  and  BUITRAGO, Diana Carolina. Experience in the use of oral lipid-lowering medicines in a group of patients followed in 12 colombian cities. Medicas UIS [online]. 2019, vol.32, n.1, pp.13-20.  Epub Oct 26, 2019. ISSN 0121-0319.


Drug use studies are important to evaluate the effectiveness and safety of drugs in daily practice, outside the controlled clinical study. Lipid-lowering drugs act on the lipid profile, decreasing the risk of cardiovascular diseases.


To describe the clinical performance and safety of the use of lipid-lowering drugs in real practice in a group of patients diagnosed with dyslipidemia.


An observational, descriptive cohort study. A cohort of patients with hypolipidemic indication for 6 months was followed in 12 cities of Colombia that belong to the biomedical registry of follow-up of patients treated with medicines from the Abbott portfolio. Baseline demographic and clinical variables, safety and efectivity of the drugs were measured on the lipid profile at 3 and 6 months.


501 patients received lipid-lowering agents. Statins alone decreased the low density (LDL) cholesterol of 249 mg / dL (RIQ = 226-268) at baseline to 190 (177.6-210) and 170 (108-170) at the second and third measurements, respectively. For statin + ezetimibe, from 167 mg / dL (RIQ = 139-184) to 132 (110-150) and 128.5 (101.5-128.5). Fenofibrate decreased triglycerides from 275 mg / dL (RIQ = 219-346) to 201 (172-239) and 150.5 (140-150.5).


The administration of statins alone or in combination decreased LDL and total cholesterol levels, while fenofibrate demonstrated its effectiveness in lowering triglycerides. No adverse effects were reported. There was partial adherence of the treating physician to GPC for dyslipidemias. There were no adverse events. MÉD.UIS.2019;32(1):13-20.

Keywords : Pharmacovigilance; Hypolipidemic Agents; Cholesterol; Registries; Dyslipidemia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )